Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada.

Catherine Beauchemin Kimberly Guinan D Claveau S Frédéric Dufresne Coleman Rotstein

Published in: Expert review of pharmacoeconomics & outcomes research (2021)

This study demonstrates that, in comparison to voriconazole, isavuconazole is a cost-effective strategy for the treatment of patients with suspected IPA, regardless of their life expectancy.

Keyphrases

pulmonary hypertension
pulmonary embolism
replacement therapy